|
Prediction of oncogene mutation status in non-small cell lung cancer leveraging radiomics from CT scans: A systematic review and meta-analysis with a special focus on artificial-intelligence-based methods. |
| |
|
|
|
Travel, Accommodations, Expenses - Quibim |
| |
|
|
|
Travel, Accommodations, Expenses - Quibim |
| |
Fuensanta Bellvís Bataller |
|
|
Research Funding - Quibim (Inst) |
Travel, Accommodations, Expenses - Quibim |
| |
|
|
Research Funding - Quibim (Inst) |
Patents, Royalties, Other Intellectual Property - Quibim |
Travel, Accommodations, Expenses - Quibim |
| |
|
|
|
Stock and Other Ownership Interests - Agenus; Aurinia Pharmaceuticals; Circulogene Theranostics |
|
Consulting or Advisory Role - Angiex; IGC; Imaging Endpoints; Oncacare; Rafael Pharmaceuticals; SPARC |
Patents, Royalties, Other Intellectual Property - inventor: PCT/US2008/072787, PCT/US2010/043777, PCT/US2011/020612, and PCT/US2011/037616 |
| |
|
No Relationships to Disclose |
| |
Antonio David Lázaro Sánchez |
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
Speakers' Bureau - AstraZeneca/MedImmune; Lilly |
Travel, Accommodations, Expenses - Roche; Takeda |
| |
|
|
|
Stock and Other Ownership Interests - Quibim |
Research Funding - Quibim (Inst) |
Travel, Accommodations, Expenses - Quibim |